Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program

worldpharmanewsDecember 24, 2019

Tag: Theravance Biopharma , Pfizer , JAK

PharmaSources Customer Service